Search results for " Humans"

showing 10 items of 2466 documents

Enhanced lipid peroxidation and platelet activation as potential contributors to increased cardiovascular risk in the low-HDL phenotype

2013

Background Low high‐density lipoprotein ( HDL ) levels are major predictors of cardiovascular ( CV ) events, even in patients on statin treatment with low‐density lipoprotein ( LDL ) at target. In animal models HDL s protect LDL from oxidation and blunt platelet activation. Our study aimed to examine whether HDL levels are related to in vivo oxidative stress and platelet activation, as determinants of atherothrombosis. Methods and Results Urinary 8‐iso‐PGF 2α and 11‐dehydro‐TXB 2 , in vivo markers of oxidative stress and platelet activation, respectively, were measured in 65 coronary heart disease (CHD) normocholesterolemic patients with HDL ≤35 mg/ dL , and in 47 CHD patients with HDL &gt…

MaleSettore MED/09 - Medicina InternaCoronary DiseaseDinoprostmedicine.disease_causeLipid peroxidationchemistry.chemical_compoundFenofibrateHDL cholesterolRisk FactorsCoronary Heart Diseaseoxidative stressMyocardial infarctionOriginal ResearchHypolipidemic AgentsplateletHypoalphalipoproteinemiasFenofibrateMiddle AgedAged; Arachidonic Acids; Case-Control Studies; Cholesterol HDL; Coronary Disease; Cross-Sectional Studies; Dinoprost; Exercise; Exercise Therapy; Female; Fenofibrate; Humans; Hypoalphalipoproteinemias; Hypolipidemic Agents; Lipid Peroxidation; Male; Middle Aged; Oxidative Stress; Phenotype; Platelet Activation; Risk Factors; Sedentary Lifestyle; Thromboxane B2; Cardiology and Cardiovascular MedicineExercise TherapyCholesterolPhenotypeSedentary LifestyleFemalelipids (amino acids peptides and proteins)exercise HDL cholesterol oxidative stress plateletCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyHDLArachidonic AcidsDiabetes mellitusInternal medicinemedicineHumansPlatelet activationExerciseAgedCreatininebusiness.industryCholesterol HDLCase-control studyPlatelet Activationmedicine.diseaseThromboxane B2Cross-Sectional StudiesEndocrinologychemistryCase-Control StudiesLipid PeroxidationSedentary BehaviorbusinessOxidative stressLipoproteinEuropean Heart Journal
researchProduct

Nonalcoholic fatty liver and metabolic syndrome in Italy: Results from a multicentric study of the Italian Arteriosclerosis society

2013

Nonalcoholic fatty liver disease (NAFLD) is associated with all the components of metabolic syndrome (MS) and might to be considered an additional component of MS itself. The Italian Society for the Study of Atherosclerosis (SISA) in 2005 started a research project aimed to study the NAFLD, using ultrasound (US), in nondiabetic MS subjects matching at least one of the ATP III criteria for HDL-C or triglycerides [TG]. Prevalence of US-NAFLD and its associated risk factors and prevalence of hypertransaminasemia and its possible determinants were evaluated. NAFLD prevalence was 0.78. Men with steatosis compared to men without steatosis were younger (P < 0.05) with higher TG (P < 0.03), homeost…

MaleSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismNonalcoholic fatty liverSex FactorSettore MED/13 - EndocrinologiaBody Mass IndexEndocrinologyNon-alcoholic Fatty Liver DiseaseRisk FactorsNonalcoholic fatty liver diseaseAtherosclerosis; Metabolic Syndrome X; Sex Factors; Humans; Lipids; Aged; Fatty Liver; Non-alcoholic Fatty Liver Disease; Body Mass Index; Italy; Logistic Models; Risk Factors; Liver; Middle Aged; Female; MaleUltrasonographyMulticentric studyMetabolic Syndrome XFatty liverGeneral MedicineArteriosclerosisLipidMiddle AgedLipidsMetabolic syndromeDiabetes and MetabolismItalyLiverAtherosclerosiFemaleHumanmedicine.medical_specialtyLogistic ModelNonalcoholic fatty liver Metabolic syndrome Lipids Multicentric studyInsulin resistanceSex FactorsDiabetes mellitusInternal medicinemedicineInternal MedicineHumansLipids; Metabolic syndrome; Multicentric study; Nonalcoholic fatty liver; Aged; Body Mass Index; Fatty Liver; Female; Humans; Italy; Lipids; Liver; Logistic Models; Male; Metabolic Syndrome X; Middle Aged; Non-alcoholic Fatty Liver Disease; Risk Factors; Sex Factors; Atherosclerosis; Endocrinology; Internal Medicine; Endocrinology Diabetes and MetabolismAgedbusiness.industryRisk Factornutritional and metabolic diseasesAmbientalemedicine.diseaseAtherosclerosisFatty LiverEndocrinologyLogistic ModelsMetabolic syndromeSteatosisbusinessBody mass index
researchProduct

Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study

2018

Abstract Background and aims Familial hypercholesterolemia (FH) is an inherited disorder characterized by high levels of blood cholesterol from birth and premature coronary heart disease. Thus, the identification of FH patients is crucial to prevent or delay the onset of cardiovascular events, and the availability of a tool helping with the diagnosis in the setting of general medicine is essential to improve FH patient identification. Methods This study evaluated the performance of the Dutch Lipid Clinic Network (DLCN) score in FH patients enrolled in the LIPIGEN study, an Italian integrated network aimed at improving the identification of patients with genetic dyslipidaemias, including FH.…

MaleSettore MED/09 - Medicina InternaGenetic testingPredictive Value of TestFamilial hypercholesterolemia030204 cardiovascular system & hematologyDecision Support Technique0302 clinical medicineRetrospective StudieRisk FactorsCardiovascular DiseaseGenetic MarkerProspective Studies030212 general & internal medicineAge of OnsetProspective cohort studyeducation.field_of_studymedicine.diagnostic_testMiddle AgedDutch Lipid Clinic Network score; Familial hypercholesterolemia; Genetic testing; Adult; Age of Onset; Biomarkers; Cardiovascular Diseases; Cholesterol LDL; Female; Genetic Markers; Genetic Predisposition to Disease; Genetic Testing; Humans; Hyperlipoproteinemia Type II; Italy; Male; Middle Aged; Phenotype; Predictive Value of Tests; Prospective Studies; Reproducibility of Results; Retrospective Studies; Risk Assessment; Risk Factors; Decision Support Techniques; Mutation3. Good healthCholesterolPhenotypeItalyCardiovascular DiseasesFemaleCardiology and Cardiovascular MedicineHumanAdultGenetic Markersmedicine.medical_specialtyDutch Lipid Clinic Network scorePopulationFamilial hypercholesterolemiaReproducibility of ResultPhysical examinationDutch Lipid Clinic Network score; Familial hypercholesterolemia; Genetic testing; Cardiology and Cardiovascular MedicineRisk AssessmentLDLDecision Support TechniquesHyperlipoproteinemia Type II03 medical and health sciencesPredictive Value of TestsInternal medicinemedicineHumansGenetic Predisposition to DiseaseFirst-degree relativeseducationRetrospective StudiesGenetic testingDutch Lipid Clinic Network score; Familial hypercholesterolemia; Genetic testingbusiness.industryRisk FactorReproducibility of ResultsSettore MED/13 - ENDOCRINOLOGIABiomarkerCholesterol LDLmedicine.diseaseMissing dataDutch Lipid Clinic Network score Familial hypercholesterolemia Genetic testingProspective StudieMutationAge of onsetbusinessBiomarkers
researchProduct

Testing the Short-Term Efficacy of a Lipid-Lowering Nutraceutical in the Setting of Clinical Practice: A Multicenter Study

2015

Abstract The main guidelines for cardiovascular disease prevention suggest that nutraceuticals could be an efficacious tool to improve lipid pattern. Our aim was to carry out a clinical trial comparing the metabolic effects of a combined nutraceutical containing both red yeast rice and polyunsaturated fatty acids (PUFAs) and a phytosterol-based approach in a setting of clinical practice. This was a multicenter open study with parallel control. We consecutively enrolled 107 pharmacologically untreated subjects affected by primary polygenic hypercholesterolemia and metabolic syndrome, assigned to 8-week treatment with a combined treatment with red yeast rice (Dif1Stat®, including 5 mg monacol…

MaleSettore MED/09 - Medicina InternaMedicine (miscellaneous)PharmacologyTriglycerideDietary supplements; Hypercholesterolemia; Monacolins; Nutraceuticals; Phytosterols; PUFA; Red yeast rice; Medicine (miscellaneous); Nutrition and DieteticsDietary supplementchemistry.chemical_compoundPhytosterolAnticholesteremic AgentMetabolic Syndromechemistry.chemical_classificationMonacolinNutrition and DieteticsAnticholesteremic AgentsPhytosterolPhytosterolsDietary supplements; Hypercholesterolemia; Monacolins; Nutraceuticals; Phytosterols; PUFA; Red yeast rice; Adult; Anticholesteremic Agents; Biological Products; Cholesterol; Cholesterol LDL; Fatty Acids Unsaturated; Female; Humans; Hypercholesterolemia; Lipids; Lovastatin; Male; Metabolic Syndrome; Middle Aged; Phytosterols; Treatment Outcome; Triglycerides; Dietary Supplements; Medicine (miscellaneous); Nutrition and DieteticsLipidMiddle AgedDietary supplementsLipidsCholesterolTreatment OutcomeBiochemistryFatty Acids UnsaturatedBiological ProductFemalelipids (amino acids peptides and proteins)NutraceuticalNutraceuticalsLovastatinFull CommunicationsHumanmedicine.drugPolyunsaturated fatty acidAdultHypercholesterolemiaBiologyNutraceuticalMonacolinsmedicineRed yeast riceHumansLovastatinTriglyceridesBiological ProductsCholesterolCholesterol LDLmedicine.diseaseClinical trialRed yeast ricechemistryMetabolic syndromePUFAJournal of Medicinal Food
researchProduct

Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study

2015

Abstract Background It is well known that atrial fibrillation (AF) and chronic kidney disease (CKD) are associated with a higher risk of stroke, and new evidence links AF to cognitive impairment, independently from an overt stroke (CI). Our aim was to investigate, assuming an underlying role of atrial microembolism, the impact of CI and CKD in elderly hospitalized patients with AF. Methods We retrospectively analyzed the data collected on elderly patients in 66 Italian hospitals, in the frame of the REPOSI project. We analyzed the clinical characteristics of patients with AF and different degrees of CI. Multivariate logistic analysis was used to explore the relationship between variables an…

MaleSettore MED/09 - Medicina InternaREPOSI studyKidneyDisability EvaluationRetrospective StudieRisk Factorshospitalized patientAtrial Fibrillation80 and overOdds RatioLS4_4Renal InsufficiencyChronicMultivariate AnalysiStrokeAged 80 and overMedicine (all)BrainAtrial fibrillationStrokeFemaleatrial microembolismHumanGlomerular Filtration Ratemedicine.medical_specialtySocio-culturaleRenal functionelderlyCognition DisorderInternal medicineThromboembolismmedicineInternal MedicineHumansRenal insufficiency chronicHeart AtriaIntensive care medicineAged; Anticoagulants; Atrial fibrillation; Dementia; Renal insufficiency chronic; Stroke; Aged; Aged 80 and over; Anticoagulants; Atrial Fibrillation; Brain; Cognition Disorders; Dementia; Disability Evaluation; Female; Glomerular Filtration Rate; Heart Atria; Humans; Kidney; Male; Multivariate Analysis; Odds Ratio; Renal Insufficiency Chronic; Retrospective Studies; Risk Factors; Stroke; ThromboembolismAgedRetrospective Studiesbusiness.industryRisk FactorSettore MED/09 - MEDICINA INTERNAAnticoagulantAnticoagulantsRetrospective cohort studyOdds ratiomedicine.diseaseAtrial fibrillationBlood pressureHeart failureMultivariate AnalysisAged Anticoagulants Atrial fibrillation Dementia Renal insufficiency chronic Stroke.Aged; Anticoagulants; Atrial fibrillation; Dementia; Renal insufficiency chronic; Strokeatrial microembolism; elderly; hospitalized patients; REPOSI study;DementiabusinessCognition DisordersKidney diseaseAged; Anticoagulants; Atrial fibrillation; Dementia; Renal insufficiency chronic; Stroke; Aged; Aged 80 and over; Anticoagulants; Atrial Fibrillation; Brain; Cognition Disorders; Dementia; Disability Evaluation; Female; Glomerular Filtration Rate; Heart Atria; Humans; Kidney; Male; Multivariate Analysis; Odds Ratio; Renal Insufficiency Chronic; Retrospective Studies; Risk Factors; Stroke; Thromboembolism; Internal Medicine; Medicine (all)
researchProduct

Determinants of enhanced thromboxane biosynthesis in renal transplantation

2001

Determinants of enhanced thromboxane biosynthesis in renal transplantation.BackgroundDespite great improvement in patient and graft survival, the long-term morbidity and mortality in renal transplant recipients (RTRs) are still significant, with a high incidence of cardiovascular disease-related deaths.MethodsWe investigated thromboxane (TXA2) biosynthesis and endothelial and coagulative activation in 65 patients who received a renal transplant.ResultsThe rate of TXA2 biosynthesis (urinary 11-dehydro-TXB2 excretion largely reflects platelet TXA2 production in vivo) was significantly (P < 0.0001) higher in RTRs than in healthy subjects. Plasma von Willebrand factor (vWF) and thrombin-antithr…

MaleSettore MED/09 - Medicina InternaThromboxanegraft survivalThromboxanevon Willebrand factorImmunosuppressive AgentThromboxane A2chemistry.chemical_compoundReference ValuesRenal Dialysicardiovascular diseaseReference ValuePlateletPostoperative PeriodKidney transplantationKidneyimmunosuppressionnephrotoxicityThromboxanesMiddle AgedCholesterolmedicine.anatomical_structureNephrologyCyclosporineFemaleCardiovascular disease; Graft survival; Immunosuppression; Kidney transplantation; Nephrotoxicity; Von Willebrand factor; Adult; Antithrombin III; Cardiovascular Diseases; Cholesterol; Cyclosporine; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Male; Middle Aged; Peptide Hydrolases; Postoperative Period; Reference Values; Renal Dialysis; Thromboxanes; von Willebrand Factor; Kidney Transplantation; NephrologyImmunosuppressive AgentsHumancirculatory and respiratory physiologyAdultmedicine.medical_specialtyAntithrombin IIIUrologykidney transplantationFollow-Up StudieEndothelial activationRenal DialysismedicineHumansPlatelet activationcardiovascular disease; cardiovascular diseases; graft survival; immunosuppression; kidney transplantation; nephrotoxicity; von willebrand factorbusiness.industrymedicine.diseasecardiovascular diseasesTransplantationPeptide HydrolasechemistryImmunologybusinessFollow-Up StudiesPeptide HydrolasesKidney International
researchProduct

Risk factors for hospital readmission of elderly patients

2012

Background: The aim of this study was to identify which factors were associated with a risk of hospital readmission within 3 months after discharge of a sample of elderly patients admitted to internal medicine and geriatric wards. Methods: Of the 1178 patients aged 65 years or more and discharged from one of the 66 wards of the 'Registry Politerapie SIMI (REPOSI)' during 2010, 766 were followed up by phone interview 3 months after discharge and were included in this analysis. Univariate and multivariate logistic regression models were used to evaluate the association of several variables with rehospitalization within 3 months from discharge. Results: Nineteen percent of patients were readmi…

MaleSettore MED/09 - Medicina InternaTime FactorsRisk factors; internal medicine; Geriatric patient; hospital admissionLogistic regressionElderly; Hospital readmission; Internal medicine and geriatric wards; Risk factorsElderlyInternal medicine and geriatric wards80 and overElderly; Hospital readmission; Internal medicine and geriatric wards; Risk factors; Aged; Aged 80 and over; Female; Geriatrics; Hospital Departments; Humans; Internal Medicine; Male; Patient Readmission; Risk Factors; Time Factors; Internal MedicineMedical diagnosisAged Aged; 80 and over Female Geriatrics Hospital Departments Humans Internal Medicine Male Patient Readmission; statistics /&/ numerical data Risk Factors Time FactorsAged 80 and overGeriatricsUnivariate analysisvascular diseaseHospital readmissionSettore MED/45 - Scienze Infermieristiche Generali Cliniche E PediatricheAgeing; readmissionstatistics /&/ numerical dataHospital DepartmentFemaleliver diseaseHumanmedicine.medical_specialtyTime FactorHospital DepartmentsMEDLINEHospital readmission Internal medicine and geriatric wards Risk factors Elderlyelderly patientsPatient ReadmissionNOInternal MedicinemedicineHumansRegistry Politerapie SIMI (REPOSI)Adverse effectAgedreadmissionbusiness.industryRisk FactorUnivariatemedicine.diseaseComorbidityHospital readmission; elderly patients; Registry Politerapie SIMI (REPOSI); vascular disease; liver diseaseHospital readmission; Internal medicine and geriatric wards; Risk factors; Elderlyelderly; hospital readmission; risk factors; internal medicine and geriatric wardsInternal medicine and geriatric wardAgeingGeriatric patienthospital admissionRisk factorsGeriatricsEmergency medicinebusinessGeriatricEuropean Journal of Internal Medicine
researchProduct

Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver …

2015

In many countries, first-generation protease inhibitors (PIs)/peginterferon/ribavirin (P/R) still represent the only treatment option for HCV-infected patients. Subjects with advanced disease and previous failure to P/R urgently need therapy, but they are under-represented in clinical trials. All treatment-experienced F3/4 Metavir patients who received boceprevir (BOC)+P/R in the Italian-Spanish Name Patient Program have been included in this study. Multivariate logistic regression analysis (MLR) was used to identify baseline and on-treatment predictors of SVR and adverse events (AEs). Four hundred and sixteen patients, mean age 57.7 (range 25-78 years), 70% males, 69.5% (289/416) F4, 14% (…

MaleSettore MED/09 - Medicina Internaboceprevir; cirrhosis; first-generation protease inhibitors; hepatitis C; IFN-based therapy; Adult; Aged; Antiviral Agents; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Male; Middle Aged; Proline; RNA Viral; Ribavirin; Spain; Treatment Outcome; Viral Load; Hepatology; Infectious Diseases; Virology; Medicine (all)Hepacivirusboceprevir; cirrhosis; first-generation protease inhibitors; hepatitis C; IFN-based therapy; Adult; Aged; Antiviral Agents; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Male; Middle Aged; Proline; RNA Viral; Ribavirin; Spain; Treatment Outcome; Viral Load; Hepatology; Virology; Infectious DiseasesGastroenterologyIFN-based therapy; boceprevir; cirrhosis; first-generation protease inhibitors; hepatitis Cfirst-generation protease inhibitorchemistry.chemical_compoundLiver diseaseboceprevirMedicineViralChronicSettore MED/12 - Gastroenterologiaboceprevir; cirrhosis; first-generation protease inhibitors; hepatitis C; IFN-based therapy; Adult; Aged; Antiviral Agents; Drug Therapy; Combination; Female; Hepacivirus; Hepatitis C; Chronic; Humans; Interferon-alpha; Italy; Male; Middle Aged; Proline; RNA; Viral; Ribavirin; Spain; Treatment Outcome; Viral Load; Hepatology; Infectious Diseases; Virology; Medicine (all)Medicine (all)virus diseasesHepatitis CMiddle AgedViral LoadSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis CInfectious DiseasesTreatment OutcomeItalyHCVCombinationRNA ViralDrug Therapy CombinationFemaleViral loadHumanAdultmedicine.medical_specialtyProlineAlpha interferonInfectious DiseaseAntiviral AgentsDrug TherapyVirologyInternal medicineBoceprevirRibavirinboceprevir; cirrhosis; first-generation protease inhibitors; hepatitis c; IFN-based therapy; adult; aged; antiviral agents; drug therapy combination; female; hepacivirus; hepatitis c chronic; humans; interferon-alpha; italy; male; middle aged; proline; RNA viral; ribavirin; spain; treatment outcome; viral load; hepatology; infectious diseases; virologyHumansDecompensationAdverse effectAgedAntiviral AgentIFN-based therapyHepaciviruHepatologybusiness.industryRibavirincirrhosisInterferon-alphaHepatitis C Chronicmedicine.diseasedigestive system diseasesboceprevir; cirrhosis; first-generation protease inhibitors; hepatitis C; IFN-based therapy; Adult; Aged; Antiviral Agents; Drug Therapy Combination; Female; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Male; Middle Aged; Proline; RNA Viral; Ribavirin; Spain; Treatment Outcome; Viral Loadfirst-generation protease inhibitorschemistrySpainImmunologyRNAbusinesscirrhosi
researchProduct

Cardiovascular disease, chronic kidney disease, and diabetes mortality burden of cardiometabolic risk factors from 1980 to 2010: A comparative risk a…

2014

High blood pressure, blood glucose, serum cholesterol, and BMI are risk factors for cardiovascular diseases and some of these factors also increase the risk of chronic kidney disease and diabetes. We estimated mortality from cardiovascular diseases, chronic kidney disease, and diabetes that was attributable to these four cardiometabolic risk factors for all countries and regions from 1980 to 2010.

MaleSettore MED/09 - Medicina Internakidney diseaseEndocrinology Diabetes and Metabolismhumanoscoste de las enfermedadesDiseaseGlobal HealthCohort StudiesEndocrinologyCost of Illnesscardiovascular diseaseHealth TransitionRisk Factorstransición sanitariaestudios prospectivosRenal Insufficiency Chronic -- complications -- epidemiology -- mortalityevaluación de riesgosRenal InsufficiencyProspective StudiesChronicestudios de cohortesMetabolic Syndromeeducation.field_of_studydiabetesMortality rateAge Factors; Cardiovascular Diseases; Cohort Studies; Cost of Illness; Diabetes Complications; Female; Health Surveys; Humans; Male; Metabolic Syndrome X; Prospective Studies; Renal Insufficiency Chronic; Risk Assessment; Risk Factors; Sex Factors; Spatio-Temporal Analysis; Global Health; Health Transition; Internal Medicine; Endocrinology Diabetes and Metabolism; EndocrinologyMetabolic Syndrome XCardiovascular Diseases -- complications -- epidemiology -- mortalityAge FactorsCardiovascular diseaseDiabetes Mellitus chronic kidney diseaseDiabetes Complications -- epidemiology -- mortalitySciences bio-médicales et agricolesDiabetes and MetabolismCardiovascular Diseasesencuestas de saludFemaleanálisis temporoespacialRisk assessmentcomplicaciones de la diabetesinsuficiencia renalmedicine.medical_specialtyCardiovascular disease; kidney disease; diabetes mortalityPopulationenfermedades cardiovascularesMetabolic Syndrome X -- complications -- epidemiology -- mortalityRisk AssessmentArticleDiabetes ComplicationsSex FactorsSpatio-Temporal Analysiscardiovascular disease; chronic kidney disease; diabetes; mortalityInternal medicineEnvironmental healthDiabetes mellitusmedicineAge Factors; Cardiovascular Diseases; Cohort Studies; Cost of Illness; Diabetes Complications; Female; Health Surveys; Humans; Male; Metabolic Syndrome X; Prospective Studies; Renal Insufficiency Chronic; Risk Assessment; Risk Factors; Sex Factors; Spatio-Temporal Analysis; Global Health; Health Transition; Endocrinology Diabetes and Metabolism; Internal Medicine; EndocrinologyInternal Medicinefactores de riesgoHumansRisk factorRenal Insufficiency Chroniceducationbusiness.industrydiabetes mortalitymedicine.diseasemortalityHealth SurveysEndocrinologyRelative riskAge Factors; Cardiovascular Diseases/complications; Cardiovascular Diseases/epidemiology; Cardiovascular Diseases/mortality; Cohort Studies; Cost of Illness; Diabetes Complications/epidemiology; Diabetes Complications/mortality; Female; Global Health; Health Surveys; Health Transition; Humans; Male; Metabolic Syndrome X/complications; Metabolic Syndrome X/epidemiology; Metabolic Syndrome X/mortality; Prospective Studies; Renal Insufficiency Chronic/complications; Renal Insufficiency Chronic/epidemiology; Renal Insufficiency Chronic/mortality; Risk Assessment; Risk Factors; Sex Factors; Spatio-Temporal Analysisbusinesschronic kidney diseaseKidney diseaseThe Lancet Diabetes and Endocrinology
researchProduct

Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine.

2013

Objective Obesity is a mild, long-lasting inflammatory disease and, as such, could increase the inflammatory burden of rheumatoid arthritis (RA). The study aim was to determine whether obesity represents a risk factor for a poor remission rate in RA patients requiring anti–tumor necrosis factor α (anti-TNFα) therapy for progressive and active disease despite treatment with methotrexate or other disease-modifying antirheumatic drugs. Methods Patients were identified from 15 outpatient clinics of university hospitals and hospitals in Italy taking part in the Gruppo Italiano di Studio sulle Early Arthritis network. Disease Activity Score in 28 joints (DAS28), body mass index (BMI; categorized …

MaleSettore MED/16 - REUMATOLOGIAArthritisGastroenterologyReceptors Tumor Necrosis FactorEtanerceptEtanerceptArthritis RheumatoidRheumatoidMonoclonalReceptorsMedicineOutpatient clinicLongitudinal StudiesRegistriesPrecision Medicineskin and connective tissue diseasesHumanizedRemission InductionAntibodies MonoclonalIndividualized MedicineMiddle AgedTreatment OutcomeRheumatoid arthritisAntirheumatic AgentsFemaleDrugmedicine.drugmusculoskeletal diseasesmedicine.medical_specialtyAdalimumab; Aged; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthritis Rheumatoid; Dose-Response Relationship Drug; Etanercept; Female; Humans; Immunoglobulin G; Infliximab; Longitudinal Studies; Male; Middle Aged; Obesity; Precision Medicine; Receptors Tumor Necrosis Factor; Registries; Remission Induction; Treatment Outcome; Tumor Necrosis Factor-alphaAntibodies Monoclonal HumanizedAntibodiesDose-Response RelationshipRheumatologyInternal medicineAdalimumabHumansObesityRisk factorAgedDose-Response Relationship Drugbusiness.industryTumor Necrosis Factor-alphaArthritisAdalimumabmedicine.diseaseInfliximabRheumatologyInfliximabAged; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthritis Rheumatoid; Dose-Response Relationship Drug; Female; Humans; Immunoglobulin G; Individualized Medicine; Longitudinal Studies; Male; Middle Aged; Obesity; Receptors Tumor Necrosis Factor; Registries; Remission Induction; Treatment Outcome; Tumor Necrosis Factor-alphaImmunoglobulin GImmunologybusinessTumor Necrosis FactorArthritis careresearch
researchProduct